Paper · 39959686

Complex Roles of PTPN11/SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy.

Scheiter A and 3 others. Annu Rev Cancer Biol, 2024. Cited by 14 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Complex Roles of PTPN11/SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy. Papers, record 39959686. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39959686

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Complex Roles of PTPN11/SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy.; PubMed
Journal: Annu Rev Cancer Biol; PubMed
Year: 2024; PubMed
Publication types: Journal Article; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/39959686/; PubMed
DOI: https://doi.org/10.1146/annurev-cancerbio-062722-013740; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC11824402/; PubMed
The journal: https://conductscience.org/library/journal-index/101686182; PubMed
Citations, by iCite: 14; iCite
Relative citation ratio, by iCite: 1.62, provisional; iCite
Revised in PubMed: 2025-06-02; PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Scheiter A	Alexander
2	Lu LC	Li-Chun
3	Gao LH	Lilian H
4	Feng GS	Gen-Sheng

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by	Source
P01 AG073084	NIA NIH HHS	United States	P01AG073084	PubMed	NIH RePORTER
R01 CA236074	NCI NIH HHS	United States	R01CA236074	PubMed	NIH RePORTER
R01 CA239629	NCI NIH HHS	United States	R01CA239629	PubMed	NIH RePORTER
R01 DK128320	NIDDK NIH HHS	United States	R01DK128320	PubMed	NIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References129

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	29,505,847	Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET.	J Hepatol	2018	https://conductscience.org/library/papers/29505847	PubMed
2	24,981,838	Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis.	Cell Metab	2014	https://conductscience.org/library/papers/24981838	PubMed
3	16,369,543	A role for the scaffolding adapter GAB2 in breast cancer.	Nat Med	2006	https://conductscience.org/library/papers/16369543	PubMed
4	21,339,643	Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.	J Clin Invest	2011	https://conductscience.org/library/papers/21339643	PubMed
5	26,460,004	Shp2 and Pten have antagonistic roles in myeloproliferation but cooperate to promote erythropoiesis in mammals.	Proc Natl Acad Sci U S A	2015	https://conductscience.org/library/papers/26460004	PubMed
6	20,577,567	Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene.	PLoS Genet	2010	https://conductscience.org/library/papers/20577567	PubMed
7	1,708,916	SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins.	Science	1991	https://conductscience.org/library/papers/1708916	PubMed
8	23,980,151	Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains.	Proc Natl Acad Sci U S A	2013	https://conductscience.org/library/papers/23980151	PubMed
9	33,418,513	Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.	Curr Opin Chem Biol	2021	https://conductscience.org/library/papers/33418513	PubMed
10	7,681,217	Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation.	Science	1993	https://conductscience.org/library/papers/7681217	PubMed

1 to 10 of 129

See all 129 references

Cited by9

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.

PMID	Title	Journal	Year	In Papers	Source
42,799,479	Identification and Preliminary mRNA Validation of Key Genes Associated with Tolerogenic Dendritic Cells in Keloid Based on Transcriptome Data.	Clin Cosmet Investig Dermatol	2026	https://conductscience.org/library/papers/42799479	PubMed
41,959,461	High-throughput biochemical phenotyping of SHP2 variants reveals the molecular basis of diseases and allosteric drug inhibition.	bioRxiv	2026	https://conductscience.org/library/papers/41959461	PubMed
41,510,158	Condensatopathies as a mechanistic framework for disease and integrated theranostic intervention.	Theranostics	2026	https://conductscience.org/library/papers/41510158	PubMed
41,429,940	Proximity-labeling proteomics reveals remodeled interactomes and altered localization of pathogenic SHP2 variants.	EMBO Rep	2026	https://conductscience.org/library/papers/41429940	PubMed
41,225,768	The pathogenic E139D mutation stabilizes a non-canonical active state of the multi-domain phosphatase SHP2.	Protein Sci	2025	https://conductscience.org/library/papers/41225768	PubMed
41,181,611	Alkaloid-driven multi-target synergy of Tripterygium wilfordii polyglycosides overcomes cisplatin resistance in ovarian cancer by coordinated inhibition of PTPN11/EGFR/JAK signaling.	Front Pharmacol	2025	https://conductscience.org/library/papers/41181611	PubMed
40,661,614	Proximity-labeling proteomics reveals remodeled interactomes and altered localization of pathogenic SHP2 variants.	bioRxiv	2025	https://conductscience.org/library/papers/40661614	PubMed
40,631,229	The pathogenic E139D mutation stabilizes a non-canonical active state of the multi-domain phosphatase SHP2.	bioRxiv	2025	https://conductscience.org/library/papers/40631229	PubMed
40,605,709	PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes.	Haematologica	2025	https://conductscience.org/library/papers/40605709	PubMed

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
EPHB2	2,048	PubTator's text mining	https://conductscience.org/library/genes/2048	NCBI Gene
PTPN11	5,781	PubTator's text mining	https://conductscience.org/library/genes/5781	NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39959686

GET https://conductscience.org/api/papers/v1/39959686/references?page=2

API reference For AI assistants